Extended Data Fig. 4: Relative percent change from baseline in a, total cholesterol, b, HDL-C, and c, LDL-C at week 6, and d, liver fat as assessed by CAP over time to week 6, in patients with NAFLD. | Nature Medicine

Extended Data Fig. 4: Relative percent change from baseline in a, total cholesterol, b, HDL-C, and c, LDL-C at week 6, and d, liver fat as assessed by CAP over time to week 6, in patients with NAFLD.

From: ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials

Extended Data Fig. 4

Placebo n = 12, PF-05221304 n = 22, PF-06865571 n = 24, PF-05221304 and PF-06865571 n = 26. Data represent LSM (90% CI). Statistical significance versus placebo was pre-defined as a two-sided p value of <0.05 based on an ANCOVA model in panels a–c, and from an MMRM model with no adjustment for multiple comparisons in panel d. ANCOVA, analysis of covariance; CAP, controlled attenuation parameter; CI, confidence interval; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LSM, least squares mean; MMRM, mixed-effects model for repeated measures; NAFLD, non-alcoholic fatty liver disease; PF’1304, PF-05221304 monotherapy; PF’5571, PF-06865571 monotherapy; PF’1304 + PF’5571, PF-05221304 and PF-06865571 co-administration.

Source data

Back to article page